Trastuzumab deruxtecan
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Unresectable Breast Cancer
Conditions
Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer, HER2-positive Breast Cancer
Trial Timeline
Apr 22, 2024 → Jul 7, 2025
NCT ID
NCT06386263About Trastuzumab deruxtecan
Trastuzumab deruxtecan is a pre-clinical stage product being developed by Daiichi Sankyo for Unresectable Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT06386263. Target conditions include Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer.
What happened to similar drugs?
1 of 20 similar drugs in Unresectable Breast Cancer were approved
Approved (1) Terminated (1) Active (18)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07015697 | Phase 1 | Recruiting |
| NCT06750484 | Phase 2 | Recruiting |
| NCT05982678 | Phase 2 | Recruiting |
| NCT06386263 | Pre-clinical | Completed |
| NCT06210776 | Pre-clinical | Recruiting |
| NCT05950945 | Phase 3 | Recruiting |
| NCT05993234 | Pre-clinical | Recruiting |
| NCT05945732 | Pre-clinical | Recruiting |
| NCT05458401 | Pre-clinical | Completed |
| NCT05246514 | Phase 2 | Active |
| NCT04989816 | Phase 2 | Completed |
| NCT04739761 | Phase 3 | Active |
| NCT04644237 | Phase 2 | Completed |
| NCT04639219 | Phase 2 | Active |
| NCT04482309 | Phase 2 | Recruiting |
| NCT04752059 | Phase 2 | Completed |
| NCT04420598 | Phase 2 | Completed |
| NCT04014075 | Phase 2 | Completed |
| NCT03505710 | Phase 2 | Terminated |
Competing Products
20 competing products in Unresectable Breast Cancer